Traders Buy Gilead Sciences, Inc. (GILD) on Weakness

Traders bought shares of Gilead Sciences, Inc. (NASDAQ:GILD) on weakness during trading hours on Monday. $118.70 million flowed into the stock on the tick-up and $100.63 million flowed out of the stock on the tick-down, for a money net flow of $18.07 million into the stock. Of all stocks tracked, Gilead Sciences had the 29th highest net in-flow for the day. Gilead Sciences traded down ($0.92) for the day and closed at $72.85

A number of analysts have recently commented on the company. Argus downgraded Gilead Sciences from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $73.25 to $73.77 in a research note on Monday. Mizuho boosted their price objective on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research note on Friday, October 27th. BMO Capital Markets dropped their price objective on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a research note on Friday, October 27th. Finally, J P Morgan Chase & Co set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and an average price target of $84.87.

The stock has a market cap of $95,140.00, a P/E ratio of 7.70, a PEG ratio of -1.24 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter in the previous year, the firm earned $2.75 EPS. The firm’s revenue was down 13.2% compared to the same quarter last year. sell-side analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.82%. Gilead Sciences’s dividend payout ratio is presently 23.66%.

In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the transaction, the executive vice president now owns 77,363 shares of the company’s stock, valued at approximately $5,788,299.66. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $83.11, for a total value of $6,094,705.63. Following the completion of the transaction, the insider now directly owns 2,996,766 shares of the company’s stock, valued at approximately $249,061,222.26. The disclosure for this sale can be found here. Insiders have sold a total of 446,819 shares of company stock valued at $36,269,486 in the last three months. 1.30% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of GILD. Strategic Advisors LLC acquired a new position in Gilead Sciences in the 1st quarter valued at approximately $1,041,000. Point View Wealth Management Inc. grew its stake in shares of Gilead Sciences by 21.4% in the 1st quarter. Point View Wealth Management Inc. now owns 7,851 shares of the biopharmaceutical company’s stock valued at $533,000 after purchasing an additional 1,385 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Gilead Sciences by 9.8% in the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after purchasing an additional 2,727,063 shares during the period. Clean Yield Group grew its stake in shares of Gilead Sciences by 16.4% in the 1st quarter. Clean Yield Group now owns 46,253 shares of the biopharmaceutical company’s stock valued at $3,142,000 after purchasing an additional 6,510 shares during the period. Finally, Ray Gerald L & Associates Ltd. grew its stake in shares of Gilead Sciences by 11.0% in the 1st quarter. Ray Gerald L & Associates Ltd. now owns 75,025 shares of the biopharmaceutical company’s stock valued at $5,096,000 after purchasing an additional 7,445 shares during the period. 74.62% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This article was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.themarketsdaily.com/2017/11/14/traders-buy-gilead-sciences-inc-gild-on-weakness.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply